Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 23, 2022, Atara Biotherapeutics, Inc. (the "Company") held its 2022 annual meeting of stockholders (the "Annual Meeting"). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2022 (the "Proxy Statement").



1.   Election of Directors

Nominee                       For            Withheld        Broker Non-Votes
Roy Baynes, M.D., Ph.D.     63,131,166       17,769,265              6,175,945
Matthew K. Fust             68,265,757       12,634,674              6,175,945
Ronald C. Renaud, Jr.       69,029,789       11,870,642              6,175,945

Each of the three nominees for director was elected to serve until the 2025 annual meeting of stockholders and until their successors are elected.



2.   Advisory vote to approve on the compensation of the Company's named
executive officers

   For        Against    Abstain   Broker Non-Votes
78,488,147   2,362,933   49,351       6,175,945

The stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.

3. Ratification of appointment of independent registered public accounting firm



   For       Against   Abstentions
86,968,307   35,221      72,848

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses